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Main objective of this study was to confirm that surgery alone is an effective and safe treatment for localised resectable
neuroblastoma except stage 2 with amplified MYCN gene (MYCNA). Of 427 eligible stages 1–2 patients, 411 had normal MYCN and
16 had MYCNA. Of the 288 stage 1 patients with normal MYCN, 1 died of complications and 16 relapsed, 2 of whom died; 5-year
relapse-free survival (RFS) and overall survival (OS) rates were 94.3% (95% confidence interval (CI): 91.6–97) and 98.9% (95% CI:
97.7–100), respectively. Of the 123 stage 2 patients with normal MYCN, 1 died of sepsis and 22 relapsed, 8 of whom died (RFS
82.8%, 95% CI: 76.2–89.5; OS 93.2%, 95% CI: 88.7–97.8). In stage 2, OS and RFS were worse for patients with elevated LDH and
unfavourable histopathology. Of 16 children with MYCNA, 7 were stage 1 (5 relapses and 4 deaths) and 9 were stage 2 (3 relapses
and 2 deaths) patients. In conclusion, surgery alone yielded excellent OS for both stage 1 and 2 neuroblastoma without MYCNA,
although stage 2 patients with unfavourable histopathology and elevated LDH suffered a high number of relapses. Both stage 1 and 2
patients with MYCNA were at greater risk of relapse.
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Neuroblastoma, the most common extracranial solid tumour in
childhood, originates from the primitive cells of the sympathetic
nervous system (Caron and Pearson, 2005). Approximately half of
the children diagnosed with neuroblastoma have metastatic
disease on diagnosis and, except for infants (De Bernardi et al,
1992), have a low probability of cure (De Bernardi et al, 2003). The
remaining children present with localised disease and have an
overall better prognosis, mainly depending on the degree of
tumour resection (Cecchetto et al, 1983; von Schweinitz et al,
2000). Indeed, completely resected tumours (INSS stage 1)
(Brodeur et al, 1993) rarely relapse and do not usually undergo
postoperative chemotherapy (Kushner et al, 1996; Alvarado et al,
2000). By contrast, localised but unresectable neuroblastomas
(INSS stage 3) require primary chemotherapy before surgical
excision is attempted, and in any case have a greater likelihood of
relapse and a lower cure rate (Garaventa et al, 2002).
An intermediate condition involves primary tumour resection
that has left behind a small residue (INSS stage 2). Some authors
have suggested leaving these tumour residues untreated
(De Bernardi et al, 1995; Perez et al, 2000); however, some of
these tumours relapse (occasionally in a disseminated form) and
then require intensive treatment, which is sometimes unsuccessful.
At present, only abnormal MYCN gene status is believed to
correlate with worse outcome in these patients, and postoperative
treatment is therefore deemed necessary only in such cases (Rubie
et al, 1997). A number of other factors, including regional lymph
node involvement (Ninane et al, 1982; Rosen et al, 1984), tumour
rupture (De Bernardi et al, 1995), unfavourable histology (Perez
et al, 2000; Shimada et al, 2001), DNA index (Bagatell et al, 2005),
and some biochemical markers (Hann et al, 1985; Zeltzer et al,
1986; Shuster et al, 1992), have been associated with greater risk of
relapse and death.
In the early 1990s, the SIOP Europe Neuroblastoma Group
(SIOPEN) activated the first Localised Neuroblastoma European
Study (LNESG1). The principal objectives of this study were to
confirm that surgery alone suffices in all stage 1 children and to
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sassess whether the same is true for stage 2 children with normal
MYCN gene status. A secondary objective of the LNESG1 study was
to establish a European registry for all localised neuroblastomas.
In this report, we describe the outcome of both stage 1 and 2
patients stratified according to MYCN gene status.
PATIENTS AND METHODS
Patient registration and eligibility
The registration of children with suspected, localised neuro-
blastoma potentially eligible for the LNESG1 Study began in
January 1995 and ended in October 1999. In an attempt to ensure
the enrolment of children who had suffered major surgery-related
complications, the investigators were requested to register all
suspected cases with non-metastatic neuroblastoma before histo-
logical confirmation. Data were collected at the Study Coordinating
Centre, located at the Institut Curie, Paris, France. Nine European
countries (Austria, Belgium, France, Italy, The Netherlands,
Portugal, Spain, Switzerland, and United Kingdom) participated
in the study.
To be eligible in the study, patients had to fulfil all of the
following criteria: age on diagnosis below 20 years, histological
diagnosis of neuroblastoma (excluding ganglioneuroma), evalua-
tion of MYCN gene status, primary tumour resectability, the
absence of metastasis, and no previous therapy. Informed consent
was provided by a parent or guardian for each patient enrolled in
the study. Study approval was obtained from the local institutional
review boards.
Diagnostic procedures and metastatic workup
The diagnostic imaging of the tumour included ultrasound scan
plus computed tomography and/or magnetic resonance imaging
(Siegel et al, 2002). These investigations were carried out in an
effort to detect features (defined as surgical risk factors) that are
believed to reduce the probability of complete tumour resection
and that lead to increased risk of surgery-related complications.
Immediate surgery was recommended for patients without surgical
risk factors, whereas the remaining patients were to receive
chemotherapy in preparation for surgery. Details regarding
surgical risk factors and surgical guidelines have been reported
elsewhere (Cecchetto et al, 2005).
Bone marrow infiltration was ruled out on the basis of four
negative specimens (two bone marrow aspirates and two trephine
core biopsies for children aged 1 year or more; 2–4 aspirates for
infants). Skeletal involvement was evaluated by MIBG (iodine-
123-metaiodobenzylguanidine scintigraphy) or by technetium-
99m-MDP scintigraphy in the absence of MIBG uptake or if
MIBG scintigraphy had not been performed prior to surgery.
Involvement of other organs, mainly the liver, lung, skin, and
distant lymph nodes, was studied by ultrasound scan and/or
computed tomography.
Biochemical studies included the assay of catecholamine
metabolites, that is vanillylmandelic acid and homovanillic acid
in the urine (Strenger et al, 2007), and lactate dehydrogenase
(LDH) assay in the serum. Vanillylmandelic acid, homovanillic
acid, and LDH levels were considered to be abnormal if they
exceeded twice the upper normal value.
Histopathology
Histological diagnosis was performed by the local pathologists
according to the Shimada system and the related classification
(Shimada et al, 1999, 2001). Non-MYCN amplified stage 2 tumours
were reviewed by an European Pathology Panel (Navarro et al,
2006).
Biological studies
To guarantee the reproducibility of the results, 11 laboratories
from 9 European countries set up an European Neuroblastoma
Quality Assessment (ENQUA) Group (Ambros et al, 2003). This
led to the establishment of common rules with regard to the
handling of tumour materials, methods, and DNA probes to be
used, and the interpretation of DNA blots and fluorescent in situ
hybridisation (FISH) analyses. The evaluation of MYCN gene
status in tumour cells was a prerequisite to enrolling patients in the
study. MYCN gene amplification (MYCNA) was defined as a copy
number of 10 or more, or a greater than fourfold increase in the
MYCN signal number in comparison with the reference probe
located on chromosome 2. Evaluation of DNA content was strongly
recommended.
Adjuvant therapy
Stage 1 patients, regardless of MYCN gene status, and stage 2
patients without MYCNA received no adjuvant therapy (except for
those with symptomatic spinal cord compression) (De Bernardi
et al, 2005) and were carefully followed up. Stage 2 patients with
MYCNA were treated according to institutional guidelines.
Follow-up
Computed tomography or magnetic resonance imaging was
performed within 1 month of surgery to assess the degree of the
residual tumour, if any. Patients were subsequently evaluated by
clinical examination and ultrasound scan at least once every
3 months in the first year, and every 3–6 months over the
following 5 years.
Tumour relapse and progression
In the event of relapse or progression, complete disease evaluation
was carried out, including histological (or cytohistological)
examination, assay of MYCN status, and metastatic workup. Local
relapse was preferentially treated by surgery and standard-
dose chemotherapy according to national protocols. Metastatic
relapse was treated according to the current national stage 4
protocols.
Statistical analyses
The prospective European registration of localised neuroblastoma
was activated in January 1995. Stage 1, 2 and 3 subjects were to be
registered. According to LNESG1 protocol, 140 stage 2 patients
without MYCNA were to be enrolled in this trial that involved
surgery as the only treatment in an effort to assess whether the
conservative approach alone was enough to keep the 3-year
survival rate above 90%. Enrollment was expected to last 3.5 years.
Four and a half years after the beginning of the study (which lasted
from January 1995 to October 1999), a total of 123 stage 2 patients
had been recruited, representing 16.7% of all localised neuro-
blastomas. At that time, the trial, as well as the prospective
registration, was closed. The frequency of clinical, biological, and
pathological features in various subgroups was compared by the
w
2 test or by two-tailed Fisher’s exact test when necessary.
Overall survival and relapse-free survival (RFS) curves were
estimated according to the Kaplan–Meier method and compared
by log-rank test, and were calculated from the day of tumour
resection. Overall survival took all deaths into account. In RFS,
local or distant recurrences were considered as events. Patients
who did not relapse were censored at the time of death or last
follow-up.
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sRESULTS
Between January 1995 and October 1999, a total of 905 children
and adolescents with suspected localised neuroblastoma were
registered in the LNESG1 Study by 107 European institutions. Of
these, 215 children were excluded for various reasons: inade-
quately assessed MYCN gene (95 cases), staging errors (47), wrong
diagnosis (28), previous treatment (13, including 5 stage 2 patients
presenting with symptomatic spinal cord compression), undefined
histology (9), parental refusal (5), and other reasons (18) (Table 1).
Of the 690 children with non-metastatic neuroblastoma, 192 had
stage 3 disease and 71 had a diagnosis of ganglioneuroma, leaving
427 eligible children with localised resectable neuroblastoma
(Table 1). Out of these 427 children, 411 (288 stage 1 and 123
stage 2) had normal MYCN gene status, whereas 16 (7 stage 1 and 9
stage 2) had MYCNA (Table 1). The following results refer to the
stage 1 and 2 patients stratified as per MYCN status.
Stage 1 and 2 patients without MYCNA
Patients’ characteristics at diagnosis The main presenting char-
acteristics of the 288 stage 1 and the 123 stage 2 children are listed
in Table 2. There was a slight male predominance (M/F ratio, 1.4)
among stage 1 patients, whereas the number of stage 2 males and
females was almost the same. The median age of both stage 1 and
stage 2 patients was 11 months, with similar percentages of
patients in the two age groups considered (0–17, X18 months).
Stage 1 patients had more abdominal tumours than stage 2 patients
(68.4 vs 49.6%; Po0.0025), and they more often had favourable
histological features, as evaluated by the local pathologists (88.4 vs
79.8%; Po0.04), normal vanillylmandelic acid (67.4 vs 44.4%;
P¼0.0008) and normal homovanillic acid urinary excretion (67.5
vs 50.7%; P¼0.015). The percentages of normal vs abnormal LDH
serum levels (93.1 vs 92.2%) and aneuploid vs di-tetraploid DNA
index (64.3 vs 61.8%) were similar.
Surgery-related complications Among the 411 stage 1 and 2
patients, 1 (a stage 1 infant) died of surgery-related complications
2 days after the operation, owing to massive bleeding and multiple
organ failure. Thirty patients (7.3%) – 17 out of 288 stage 1 (5.9%)
and 13 out of 123 stage 2 subjects (10.6%) – developed non-fatal
complications: Horner’s syndrome (6 cases), pleural effusion or
ascitis (5), renal ischaemia or damage (4), intestinal perforation
(3), serious bleeding (2), vascular damage (2), severe infections (2),
tracheostomy (1), neurological damage (1), and others (4).
Clinical course and survival
Stage 1. Patient follow-up ranged from 3 to 134 months (median,
72). Of the 288 patients, 1 died shortly after surgery (see above),
and 16 relapsed 1–48 months after diagnosis (median, 5) (Table 3);
the estimated 5-year RFS rate was therefore 94.3% (95% confidence
interval (CI): 91.6–97.0) (Figure 1A). Relapses occurred at the
site of the primary tumour in five cases, at distant sites in seven, and
both locally and at distant sites in four cases. Sites of metastases
included various combinations of the following: bone (six cases),
bone marrow (five), and liver and skin (three cases each).
Among the 10 patients who had been diagnosed between 0 and 11
months of age, relapses occurred locally, or in the liver, skin, or
bone marrow, and were interpreted as a possible evolution towards
stage 4. Five of these patients were simply observed, whereas five
were treated with a few cycles of chemotherapy; all survived
(Table 3). The remaining six patients who relapsed were older than 1
year on diagnosis; two of these died (one of progressive disease and
one of chemotherapy-related toxicity) and four survived (Table 3).
The estimated 5-year OS was 98.9% (95% CI: 97.7–100) (Figure 1B).
The 5-year OS of the 16 patients who relapsed was 87.5% (95% CI:
71.3–100).
Stage 2. Patient follow-up ranged from 10 to 137 months
(median, 80). Of the 123 patients, 1 died of sepsis due to surgery-
related spleen atrophy 18 months after tumour resection, and 22
relapsed 1–90 months after diagnosis (median, 6) (Table 4); the
estimated 5-year RFS rate was therefore 82.8% (95% CI: 76.2–89.5)
(Figure 1A). Relapses occurred locally in 13 cases, at distant sites
in 1, and both locally and at distant sites in 8. Sites of metastases
included various combinations of the following: bone (five cases),
bone marrow (five), liver and lung (one case each) (Table 4). The
median interval between diagnosis and relapse was 6 months, both
in cases of local relapse and in those of relapse at distant sites. Of
the 12 patients below 1 year of age on diagnosis who relapsed, 2
died, whereas 6 deaths occurred among the 10 patients aged 1 year
or older. The eight deaths occurred 5–55 months after relapse,
with no difference between patients who relapsed locally and those
who relapsed at distant sites (30 months for both). The estimated
5-year OS was 93.2% (95% CI: 88.7–97.8) (Figure 1B). The 5-year
OS of the 22 patients who relapsed was 56.1% (95% CI: 32.5–79.7).
Prognostic factors Analyses aimed at assessing the impact of
potential prognostic factors on OS and RFS were limited by the small
number of events. Among stage 1 patients, no analysis of OS was
possible (three events). Regarding RFS, the only prognostic factor we
identified was gender, with males relapsing more often than females
(5-year RFS 92.0 vs 97.5%; Po0.05) (Table 5). Normal LDH serum
levels were associated with greater RFS (95.6 vs 83.3%), but the
difference was not statistically significant (P¼0.061). Among stage 2
patients, no noticeable differences in either OS or RFS were observed
with regard to gender, age, lymph node infiltration, vanillylmandelic
acid and homovanillic acid urinary excretion, or DNA index
(Table 5). Patients with unfavourable histopathologic features had
significantly worse OS and RFS than those with favourable features
(96.4 vs 75.9%, Po0.0004; and 85.5 vs 61.2%, Po0.0035, respec-
tively) (Table 5). In addition, normal LDH serum levels were
significantly associated with better OS and RFS (95.7 vs 50.0%;
Po0.0001; 85.2 vs 62.5%; P¼0.050, respectively) (Table 5).
Stage 1 and 2 with MYCNA
Of the 427 children with localised resectable neuroblastoma who
were evaluated for MYCN gene status, 16 (3.7%) had abnormal
copy numbers of the gene, including 7 stage 1 and 9 stage 2
Table 1 Patients in the LNESG1 study
No of patients
Enrolled 905
Excluded 215
Inadequate MYCN gene assay 95
Staging errors 47
Wrong diagnosis 28
Undefined histology 9
Previous treatment 13
Parental refusal 5
Other reasons 18
Non-metastatic neuroblastoma 690
Ineligible for the study 263
Stage 3 192
Ganglioneuroma 71
Eligible for the study 427
Study 1 295
Without MYCNA 288
With MYCNA 7
Study 2 132
Without MYCNA 123
With MYCNA 9
LNESG1¼Localised Neuroblastoma European Study.
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spatients. Five of the seven stage 1 patients suffered relapses: four
local and one both local and in the bone and bone marrow. Four of
these five patients eventually died. Of the nine stage 2 patients who
received upfront chemotherapy according to the guidelines of the
individual participating institutions, three relapsed, all locally and
at distant sites; two eventually died.
Table 2 Stage 1 and 2 patients without MYCNA. Characteristics at diagnosis
Stage
1( n¼288) 2 (n¼123)
Characteristics No. of patients % 95% CI No. of patients % 95% CI P-value
Gender
Male 167 58 52.3–63.7 61 49.6 40.8–58.4 0.11
Female 121 42 36.3–47.7 62 50.4 41.6–59.2
M/F ratio 1.4 1
Age (months) 0.63
Median 11 11
0–17 185 64.2 58.7–69.8 76 61.8 53.2–70.4
418 103 35.8 30.2–41.3 47 38.2 29.6–46.8
Site of primary tumour o0.0025
Neck 14 4.9 2.4–7.3 7 5.7 2.3–11.4
Thorax 65 22.5 17.7–27.4 43 35 26.5–43.4
Abdomen 197 68.4 63–73.8 61 49.6 40.8–58.4
Pelvis 12 4.2 1.9–6.5 12 9.7 4.5–15
Urine VMA (247 tested) 0.0008
Normal 118 67.4 60.5–74.4 32 44.4 33–55.9
Elevated 57 32.6 25.6–39.5 40 55.6 44.1–67
Urine HVA (231tested) 0.015
Normal 108 67.5 60.2–74.8 36 50.7 39.1–62.3
Elevated 52 32.5 25.2–39.8 35 49.3 37.7–60.9
Serum LDH (276 tested) 0.79
Normal 161 93.1 89.3–96.8 95 92.2 85.3–96.6
Elevated 12 6.9 3.1–10.7 8 7.8 3.4–14.7
Histopathologic category (320 tested) o0.04
Favourable 191 88.4 84.2–92.7 83 79.8 72.1–87.5
Unfavourable 25 11.6 7.3–15.8 21 20.2 12.5–27.9
DNA index (216 tested) 0.72
Aneuploid 90 64.3 56.3–72.2 47 61.8 50.9–72.8
Di-tetraploid 50 35.7 27.8–43.6 29 38.2 27.2–49.1
HVA¼homovanillic acid; LDH¼lactate dehydrogenase; VMA¼vanillylmandelic acid.
Table 3 Relapses/progressions in 16 stage 1 patients without MYCNA
Case no. Age (months) Primary site Histopathology LDH Ploidy Site/time to relapse/progression Therapy Outcome
1 0 A — E — Skin, 4 months None CR, 81 months
2 1 A F N — B, Skin, L, 3 months None CR, 74 months
3 1 Neck F — An Local, 3 months CT CR, 122 months
4 1 A F — An Local, 10 months CT CR, 87 months
5 2 A F N — L, 2 months CT CR, 62 months
6 2 A F N An B, Skin, L, 5 months None CR, 67 months
7 5 A F N D Local, B, 11 months None CR, 58 months
8 7 A F N An BM, 1 month CT CR, 117 months
9 10 T F N An Local, 3 months None CR, 112 months
10 11 A F N D Local, 48 months CT, RT CR, 92 months
11 26 T F — An Local, 23 months CT, S CR, 37 months
12 26 A U N An B, BM, 3 months CT, S CR, 127 months
13 52 A — E D BM, 11 months None CR, 70 months
14 59 A — N — Local, B, 10 months CT CR, 89 months
15 71 T — — D Local, BM, 5 months CT DOD, 24 months
16 169 A — — — Local, B, BM, 35 months CT, RT TD, 38 months
A¼abdomen; An¼aneuploid; B¼bone; BM¼bone marrow; CR¼complete remission; CT¼chemotherapy; D¼diploid; DOD¼dead of disease; E¼elevated;
F¼favourable; L¼liver; N¼normal; RT¼radiotherapy; S¼surgery; T¼thorax; TD¼toxic death; U¼unfavourable.
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sDISCUSSION
This study focused on localised, resectable tumours and aimed at
assessing whether surgery alone is an adequate and safe treatment
for all stage 1 patients and for stage 2 patients without MYCNA
(Rubie et al, 1997). Overall, 411 out of 905 enrolled patients were
classified as either INSS stage 1 or stage 2 without MYCNA. The
288 stage 1 patients in this series did very well and had an OS of
98.9%; this is in line with previous literature reports (De Bernardi
et al, 1995; Evans et al, 1996; Kushner et al, 1996; Alvarado et al,
2000; Perez et al, 2000), and confirms that neuroblastomas that are
resected macroscopically and have normal MYCN status do not
need adjuvant therapy and are commonly salvageable in the event
of relapse. Indeed, only one of three deaths was due to disease
progression, whereas the other two were related to treatment.
Physicians should therefore avoid letting risks that are secondary
to therapy exceed the risks related to this scarcely aggressive
neoplasm. It is noteworthy that, of the 16 events recorded in these
288 stage 1 patients, all the 10 that occurred in infants did well,
although 5 of them underwent observation only after the event had
occurred. This fact was interpreted as the possible evolution
towards stage 4S disease on the basis of the very young age (less
than 6 months in 7 out of 10) and the sites of progressions (mainly
the skin, bone marrow, and primary tumour). This is possibly the
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Figure 1 Five-year RFS (A) and OS (B) according to INSS stage.
Table 4 Relapses/progressions in 22 stage 2 patients without MYCNA
Case no.
Age
(months) Primary site
INSS
stage Histopathology LDH Ploidy
Site/time to
relapse/progression Therapy Outcome
1 0 P 2A U N An Local, 6 months None CR, 134 months
2 0 P 2B F — — Local, 2 months CT LFU, 20 months
3 1 A 2B F N An Local, 5 months CT DOD, 10 months
4 2 A 2A F N An Local, 1 month CT DOD, 10 months
5 2 T 2A F N Te Local, 4 months CT CR, 105 months
6 2 A 2B F N D Local, BM, 7 months CT CR, 88 months
7 3 A 2B U N An Local, BM, 8 months CT, S CR, 112 months
8 3 P 2A F — — Local, Skin 6 months CT, S CR, 125 months
9 6 A 2B F N An Local, 14 months CT CR, 88 months
10 9 P 2B F N An Local, 13 months CT CR, 38 months
11 10 A 2B F N An B, BM, 6 months CT, RT LFU, 27 months
12 10 A 2A F N Te Local, 9 months RT Unknown
13 13 A 2A — — — Local, 15 months CT CR, 55 months
14 14 Neck 2B F — An Local, 1 month CT, S CR, 89 months
15 27 A 2A U E Te Local, B, Lung, 2 months CT, S DOD, 27months
16 42 T 2A U N Te Local, BM, B, 4 months CT, S DOD, 46 months
17 43 A 2B U E Te Local, 1 month CT, S DOD, 57 months
18 47 T 2B F N — Local, BM, 3 months CT, S DOD, 19 months
19 55 A 2B U N — Local, 36 months CT, S DOD, 77 months
20 65 A 2B U E D Local, B, 5 months S, CT DOD, 32 months
21 68 T 2A U N — Local, 26 months None CR
22 100 P 2B U N D Local, B, Liver, 92 months None LFU, 93 months
A¼abdomen; An¼aneuploid; B¼bone; BM¼bone marrow; CR¼complete remission; CT¼chemotherapy; D¼diploid; DOD¼dead of disease; E¼elevated;
F¼favourable; LFU¼lost to follow-up; N¼normal; P¼pelvis; RT¼radiotherapy; S¼surgery; T¼thorax; Te¼Tetraploid; U¼unfavourable.
Localised resectable neuroblastoma
B De Bernardi et al
1031
British Journal of Cancer (2008) 99(7), 1027–1033 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sfirst observation of this type and may reflect the increased ability
to detect stage 4S disease at an early phase, that is before the
multifocal nature of the tumour has become evident. Unlike the
other stage 1 patients, the seven with MYCNA who also underwent
a wait-and-see strategy tended to have an unfavourable course;
indeed, five of them relapsed and four eventually died, suggesting
that adjuvant chemotherapy should be seriously considered for
this rare population. A pooled analysis of existing evidence is
warranted to clarify this issue.
Of 123 stage 2 patients without MYCNA who were enrolled in this
study and who underwent observation alone after surgery, 1 died of
surgery-related complications and 22 relapsed, 8 of whom died.
Relapses occurred locally in almost all cases, with associated
metastatic spread in about half of them, thus resulting in an RFS
rate of 82.8%. The risk of relapse was significantly greater in
association with unfavourable histological features, confirming the
findings of other authors (Perez et al, 2000; Shimada et al, 2001), and
elevated LDH serum levels, although in the latter case the small
number of events precludes firm conclusions about the prognostic
significance of this parameter. However, at variance with previous
reports, the risk of relapse did not correlate significantly with the age
at diagnosis (De Bernardi et al, 1995), regional lymph node infiltration
(Ninane et al, 1982), and DNA index (Bagatell et al, 2005). These
conflicting results may be accounted for by the small number of cases
in the published series. Eight of the 22 stage 2 patients who relapsed
died of disease, and the risk of progression and death was inde-
pendent of the extent of relapse. Although the 5-year OS of 93.2% is in
line with previous literature data (Matthay et al,1 9 8 9 ;D eB e r n a r d i
et al, 1995; Perez et al, 2000), it indicates that, despite having a normal
MYCN gene status, a non-negligible proportion of these patients are
candidates for a worrisome clinical course and may die of disease
progression. Clearly, further biological studies are needed to identify
which patients might benefit from adjuvant treatment.
Interestingly, one-third of the nine stage 2 patients who had
MYCNA and therefore received adjuvant therapy on an institu-
tional basis relapsed and only two eventually died (22%), as against
the four deaths (57%) observed among the seven stage 1 patients
with MYCNA who did not receive adjuvant chemotherapy.
Although the small number of patients available for these analyses
precludes any firm conclusions, our findings underline the need for
Table 5 Five-year OS and RFS for stage 1 and stage 2 patients without MYCNA
Stage 1 Stage 2
Characteristics Cases
No. of
deaths OS P-value
No. of
events RFS P-value Cases
No. of
deaths OS P-value
No. of
events RFS P-value
288 3 98.9 16 94.3 123 9 93.2 22 82.8
Gender o0.05 0.79 0.16
Male 167 13 92 61 4 93.2 8 88.5
Female 121 3 97.5 62 5 93.4 14 77.4
Age (years) 0.91 0.07 0.90
0–17 185 10 94.5 76 3 96.0 14 81.5
X18 103 6 94.1 47 6 88.7 8 85.0
Primary site 0.79 0.45 0.076
Neck 14 1 92.9 7 1 100 2 71.4
Thorax 65 3 95.4 43 2 95.3 4 90.7
Abdomen 197 12 93.7 61 6 89.6 11 81.8
Pelvis 12 0 100 12 0 100 5 66.7
LN infiltration 0.50 0.79
Absent 0 53 3 94.3 9 83.0
Present 0 70 6 92.4 13 82.7
Serum LDH 0.061 o0.0001 0.050
Normal 161 7 95.6 95 5 95.7 15 85.2
Increased 12 2 83.3 8 4 50 3 62.5
Missing 115 20
Urine VMA 0.44 0.20 0.87
Normal 118 5 95.8 32 3 90.4 6 84.4
Increased 57 4 92.8 40 1 97.5 7 82.5
Missing 113 51
Urine HVA 0.28 0.31 0.39
Normal 108 4 96.3 36 3 91.4 8 80.6
Increased 52 4 92.1 35 1 97.1 5 85.7
Missing 128 52
Histopathologic category 0.78 o0.0004 o0.0035
Favourable 191 10 94.7 83 3 96.4 12 85.5
Unfavourable 25 1 96 21 6 75.9 9 61.2
Missing 72 19
DNA index 0.40 0.31 0.40
Aneuploid 90 7 92.2 47 3 93.6 8 83
Di-tetraploid 50 4 91.5 29 4 85.9 7 79.3
Missing 148 47
HVA¼homovanillic acid; LDH¼lactate dehydrogenase; LN¼lymph node; OS¼overall survival; RFS¼relapse-free survival; VMA¼vanillylmandelic acid.
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